an encouraging trendp = .070
In this research, despite ASP‐based regimens not showing better progress than non‐ASP‐based regimens in all cases, ASP‐based regimens in stage I/II showed an encouraging trend by achieving longer PFS, with the 1‐year PFS being 100.0% versus 36.0% ( p = .070), which indicated superior outcomes in early‐stage patients.